New directions for Alzheimer's disease research from the Jackson Laboratory Center for Alzheimer's and Dementia Research 2022 workshop

Maria A. Telpoukhovskaia; Thomas J. Murdy; Olivia J. Marola; Kevin Charland; Michael MacLean; Tain Luquez; Alexandra M. Lish; Sarah Neuner; Amy Dunn; Kristen D. Onos; Jesse Wiley; Derek Archer; Matthew J. Huentelman; Matthias Arnold; Vilas Menon; Alison Goate; Linda J. Van Eldik; Paul R. Territo; Gareth R. Howell; Gregory W. Carter; Kristen M.S. O'Connell; Catherine C. Kaczorowski

doi:10.1002/trc2.12458

New directions for Alzheimer's disease research from the Jackson Laboratory Center for Alzheimer's and Dementia Research 2022 workshop

Maria A. Telpoukhovskaia
, Thomas J. Murdy
, Olivia J. Marola
, Kevin Charland
, Michael MacLean
, Tain Luquez
, Alexandra M. Lish
, Sarah Neuner
, Amy Dunn
, Kristen D. Onos
, Jesse Wiley
, Derek Archer
, Matthew J. Huentelman
, Matthias Arnold
, Vilas Menon
, Alison Goate
, Linda J. Van Eldik
, Paul R. Territo
, Gareth R. Howell
, Gregory W. Carter

Kristen M.S. O'Connell, Catherine C. Kaczorowski

Producción científica: Review article › revisión exhaustiva

2 Citas (Scopus)

Resumen

INTRODUCTION: In September 2022, The Jackson Laboratory Center for Alzheimer's and Dementia Research (JAX CADR) hosted a workshop with leading researchers in the Alzheimer's disease and related dementias (ADRD) field. METHODS: During the workshop, the participants brainstormed new directions to overcome current barriers to providing patients with effective ADRD therapeutics. The participants outlined specific areas of focus. Following the workshop, each group used standard literature search methods to provide background for each topic. RESULTS: The team of invited experts identified four key areas that can be collectively addressed to make a significant impact in the field: (1) Prioritize the diversification of disease targets, (2) enhance factors promoting resilience, (3) de-risk clinical pipeline, and (4) centralize data management. DISCUSSION: In this report, we review these four objectives and propose innovations to expedite ADRD therapeutic pipelines.

Idioma original	English
Número de artículo	e12458
Publicación	Alzheimer's and Dementia: Translational Research and Clinical Interventions
Volumen	10
N.º	1
DOI	https://doi.org/10.1002/trc2.12458
Estado	Published - ene 1 2024

Nota bibliográfica

Publisher Copyright:
© 2024 The Authors. Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

Financiación

We thank the rest of the 2022 JAX CADR workshop participants for their discussions, ideas, and inspirations: Md Mamun Al Amin, Ashley Reed, Xiaofeng Guo, Fei Yin, Hilaree Frazier, Allan Pack, Timothy Hohman, George Kuchel, Bruce Lamb, and Tracy Young‐Pearse. We thank Bethany MacDonald for coordinating the workshop. We also thank Giorgia Schena from The Jackson Laboratory for scientific editing of this report. Licence for Figure 1 from BioRender is under agreement number: YK25IQQ2V7, and for Figure 3 is it QW265R0A99. O.J.M. is funded by the Alzheimer's Association (grant # AARF‐22‐971325); M.M. received support from T32 AG062409 from the National Institute of Health/National Institute on Aging. M.A. is supported by National Institute on Aging grants RF1AG058942, RF1AG059093, U01AG061359, U19AG063744, and R01AG069901. L.V.E. is supported by National Institutes of Health grants RF1AG064859, R01AG069930, P30AG072946, U01AG076480, and U24TR004440. G.W.C. is supported by National Institutes of Health grants U54AG054345, U19AG074866, RF1AG075701, U54AG065187, R21AG083299, RF1AG079125, U01DA051235, P30CA034196, R01EY034988, and R01EY011996 and the Jackson Laboratory. G.R.P. and P.R.T. are supported by National Institutes of Health grants U54AG054345. V.M. and T.L. are supported by National Institute of Aging grants R01AG066831. C.C.K. and M.A.T. acknowledge support from the Alzheimer's Association Zenith Fellows Award AARF‐ZEN‐21‐846037. Finally, we are grateful for the funding from the JAX Center for Alzheimer's and Dementia Research (CADR) that made this workshop possible.

Financiadores	Número del financiador
CADR
JAX Center for Alzheimer's and Dementia Research
National Institutes of Health (NIH)	R01EY011996, RF1AG064859, U54AG054345, R01EY034988, U01AG076480, U24TR004440, RF1AG079125, U01DA051235, U19AG074866, P30CA034196, U54AG065187, R21AG083299, RF1AG075701, R01AG069930, P30AG072946
National Institutes of Health (NIH)
National Institute on Aging	R01AG069901, RF1AG058942, U01AG061359, U19AG063744, AARF‐ZEN‐21‐846037, RF1AG059093, R01AG066831
National Institute on Aging
Alzheimer's Association	AARF‐22‐971325, T32 AG062409
Alzheimer's Association
Jackson Laboratory

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Good health and well being

ASJC Scopus subject areas

Clinical Neurology
Psychiatry and Mental health

Acceder al documento

10.1002/trc2.12458

Otros archivos y enlaces

Citar esto

Telpoukhovskaia, M. A., Murdy, T. J., Marola, O. J., Charland, K., MacLean, M., Luquez, T., Lish, A. M., Neuner, S., Dunn, A., Onos, K. D., Wiley, J., Archer, D., Huentelman, M. J., Arnold, M., Menon, V., Goate, A., Van Eldik, L. J., Territo, P. R., Howell, G. R., ... Kaczorowski, C. C. (2024). New directions for Alzheimer's disease research from the Jackson Laboratory Center for Alzheimer's and Dementia Research 2022 workshop. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 10(1), Artículo e12458. https://doi.org/10.1002/trc2.12458

@article{0f589717e4554141882c6a1d0b863428,

title = "New directions for Alzheimer's disease research from the Jackson Laboratory Center for Alzheimer's and Dementia Research 2022 workshop",

abstract = "INTRODUCTION: In September 2022, The Jackson Laboratory Center for Alzheimer's and Dementia Research (JAX CADR) hosted a workshop with leading researchers in the Alzheimer's disease and related dementias (ADRD) field. METHODS: During the workshop, the participants brainstormed new directions to overcome current barriers to providing patients with effective ADRD therapeutics. The participants outlined specific areas of focus. Following the workshop, each group used standard literature search methods to provide background for each topic. RESULTS: The team of invited experts identified four key areas that can be collectively addressed to make a significant impact in the field: (1) Prioritize the diversification of disease targets, (2) enhance factors promoting resilience, (3) de-risk clinical pipeline, and (4) centralize data management. DISCUSSION: In this report, we review these four objectives and propose innovations to expedite ADRD therapeutic pipelines.",

author = "Telpoukhovskaia, \{Maria A.\} and Murdy, \{Thomas J.\} and Marola, \{Olivia J.\} and Kevin Charland and Michael MacLean and Tain Luquez and Lish, \{Alexandra M.\} and Sarah Neuner and Amy Dunn and Onos, \{Kristen D.\} and Jesse Wiley and Derek Archer and Huentelman, \{Matthew J.\} and Matthias Arnold and Vilas Menon and Alison Goate and \{Van Eldik\}, \{Linda J.\} and Territo, \{Paul R.\} and Howell, \{Gareth R.\} and Carter, \{Gregory W.\} and O'Connell, \{Kristen M.S.\} and Kaczorowski, \{Catherine C.\}",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors. Alzheimer's \& Dementia: Translational Research \& Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer's Association.",

year = "2024",

month = jan,

day = "1",

doi = "10.1002/trc2.12458",

language = "English",

volume = "10",

number = "1",

}

Telpoukhovskaia, MA, Murdy, TJ, Marola, OJ, Charland, K, MacLean, M, Luquez, T, Lish, AM, Neuner, S, Dunn, A, Onos, KD, Wiley, J, Archer, D, Huentelman, MJ, Arnold, M, Menon, V, Goate, A, Van Eldik, LJ, Territo, PR, Howell, GR, Carter, GW, O'Connell, KMS & Kaczorowski, CC 2024, 'New directions for Alzheimer's disease research from the Jackson Laboratory Center for Alzheimer's and Dementia Research 2022 workshop', Alzheimer's and Dementia: Translational Research and Clinical Interventions, vol. 10, n.º 1, e12458. https://doi.org/10.1002/trc2.12458

New directions for Alzheimer's disease research from the Jackson Laboratory Center for Alzheimer's and Dementia Research 2022 workshop. / Telpoukhovskaia, Maria A.; Murdy, Thomas J.; Marola, Olivia J. et al.
En: Alzheimer's and Dementia: Translational Research and Clinical Interventions, Vol. 10, N.º 1, e12458, 01.01.2024.

Producción científica: Review article › revisión exhaustiva

TY - JOUR

T1 - New directions for Alzheimer's disease research from the Jackson Laboratory Center for Alzheimer's and Dementia Research 2022 workshop

AU - Telpoukhovskaia, Maria A.

AU - Murdy, Thomas J.

AU - Marola, Olivia J.

AU - Charland, Kevin

AU - MacLean, Michael

AU - Luquez, Tain

AU - Lish, Alexandra M.

AU - Neuner, Sarah

AU - Dunn, Amy

AU - Onos, Kristen D.

AU - Wiley, Jesse

AU - Archer, Derek

AU - Huentelman, Matthew J.

AU - Arnold, Matthias

AU - Menon, Vilas

AU - Goate, Alison

AU - Van Eldik, Linda J.

AU - Territo, Paul R.

AU - Howell, Gareth R.

AU - Carter, Gregory W.

AU - O'Connell, Kristen M.S.

AU - Kaczorowski, Catherine C.

PY - 2024/1/1

Y1 - 2024/1/1

N2 - INTRODUCTION: In September 2022, The Jackson Laboratory Center for Alzheimer's and Dementia Research (JAX CADR) hosted a workshop with leading researchers in the Alzheimer's disease and related dementias (ADRD) field. METHODS: During the workshop, the participants brainstormed new directions to overcome current barriers to providing patients with effective ADRD therapeutics. The participants outlined specific areas of focus. Following the workshop, each group used standard literature search methods to provide background for each topic. RESULTS: The team of invited experts identified four key areas that can be collectively addressed to make a significant impact in the field: (1) Prioritize the diversification of disease targets, (2) enhance factors promoting resilience, (3) de-risk clinical pipeline, and (4) centralize data management. DISCUSSION: In this report, we review these four objectives and propose innovations to expedite ADRD therapeutic pipelines.

AB - INTRODUCTION: In September 2022, The Jackson Laboratory Center for Alzheimer's and Dementia Research (JAX CADR) hosted a workshop with leading researchers in the Alzheimer's disease and related dementias (ADRD) field. METHODS: During the workshop, the participants brainstormed new directions to overcome current barriers to providing patients with effective ADRD therapeutics. The participants outlined specific areas of focus. Following the workshop, each group used standard literature search methods to provide background for each topic. RESULTS: The team of invited experts identified four key areas that can be collectively addressed to make a significant impact in the field: (1) Prioritize the diversification of disease targets, (2) enhance factors promoting resilience, (3) de-risk clinical pipeline, and (4) centralize data management. DISCUSSION: In this report, we review these four objectives and propose innovations to expedite ADRD therapeutic pipelines.

UR - https://www.scopus.com/pages/publications/85187174689

UR - https://www.scopus.com/pages/publications/85187174689#tab=citedBy

U2 - 10.1002/trc2.12458

DO - 10.1002/trc2.12458

M3 - Review article

AN - SCOPUS:85187174689

VL - 10

JO - Alzheimer's and Dementia: Translational Research and Clinical Interventions

JF - Alzheimer's and Dementia: Translational Research and Clinical Interventions

IS - 1

M1 - e12458

ER -

New directions for Alzheimer's disease research from the Jackson Laboratory Center for Alzheimer's and Dementia Research 2022 workshop

Resumen

Nota bibliográfica

Financiación

ODS de las Naciones Unidas

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto